Xenon advances two experimental pain drugs toward Phase 2
Xenon Pharmaceuticals reported positive Phase 1 findings for XEN1701 and XEN1120 at the IASP 2026 World Congress on Pain in Bangkok, held October 26–30, 2026. XEN1701 produced more than 75% NaV1.7 receptor occupancy in peripheral and central nervous system measures, while XEN1120 generated blood concentrations that preclinical models associate with pain relief. Xenon plans to begin Phase 2 proof-of-concept studies for both candidates in acute pain during H1 2027.
Why it matters
The results move two non-opioid pain programs toward proof-of-concept testing, creating upcoming clinical readouts for Xenon. The company expects both Phase 2 studies to start in H1 2027.
Key facts
- 1The XEN1701 Phase 1 program included 76 participants who received the drug and 22 who received placebo. nugget.ca
- 2XEN1701 showed more than 75% NaV1.7 receptor occupancy in both peripheral and central nervous system assessments with twice-daily dosing. nugget.ca
- 3The XEN1120 Phase 1 program enrolled 54 participants receiving the drug and 18 receiving placebo. investing.com
- 4Xenon expects to start Phase 2 acute-pain studies for XEN1701 and XEN1120 in the first half of 2027. nugget.ca
Open questions
- Material 1 reports treatment-related autonomic cardiovascular events for XEN1701 in 6.6% of participants versus 4.2% for placebo, while material 2 describes the findings as showing no notable autonomic cardiovascular effects; the materials do not fully reconcile these descriptions.
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.